Glox Therapeutics has raised £4.3m in seed funding to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria.
The Company will use the funding to establish laboratories in Oxford and Glasgow and expand its team to accelerate its bacteriocin development programme. The investment round was led by Boehringer Ingelheim Venture Fund and Scottish Enterprise.
Antimicrobial resistance (AMR) is a major public health crisis throughout the world. It is estimated that around 1.27 million people per year die as a result of AMR due to the therapeutic failure of available antibiotics.
By 2050, AMR is predicted to surpass 10 million deaths globally per year at a cost of $100 trillion dollars; hence, there is an urgent need to develop new effective antimicrobial therapeutics.
Glox Therapeutics is developing precision antibiotics utilising engineered protein bacteriocins. These novel antimicrobials exhibit remarkable potency and specificity, enabling them to effectively and selectively target Gram-negative pathogens that have already developed AMR, including Pseudomonas aeruginosa and Klebsiella pneumoniae.
Bacteriocins, which are naturally produced by bacteria, possess antimicrobial properties against strains of the same or related species.
Leveraging the power of bacteriocins, Glox Therapeutics aims to advance the field of antimicrobial therapy by overcoming resistance to traditional antibiotics.
It will focus on selectively eradicating target pathogens while preserving the patient’s microbiomes, ensuring a more balanced and effective treatment strategy with reduced side-effects.
“Our mission is to provide physicians and patients with highly potent, targeted antimicrobial therapies that can kill antibiotic-resistant bacteria for which there are diminishing options available for treatment,” said Dr James Clark (pictured), CEO, Glox Therapeutics.
“This seed funding is testament to the promise of Glox Therapeutics’ precise antibiotic therapies, and we are thrilled to have the backing of such high-calibre investors."
"This will enable us to establish laboratories and attract top-tier talent, and I’m delighted to lead the team as we embark on our pioneering bacteriocin development programme, with the first target being P. aeruginosa,” he added.
